|
Guest
|
To: Durland.fish at (no spam) yale.edu, Aag1 at (no spam) columbia.edu, gary_wormser at (no spam) nymc.edu,
scientificintegrity at (no spam) ostp.gov, pkrugman at (no spam) princeton.edu,
Stanley.fish at (no spam) fiu.edu, emcsweegan at (no spam) niaid.nih.gov, afauci at (no spam) niaid.nih.gov,
SpinLyme at (no spam) yahoogroups.com, kshepard at (no spam) calea.org, fitzmas at (no spam) gmail.com,
patrick.fitzgerald at (no spam) usdoj.gov, modelt1918 at (no spam) sbcglobal.net,
jdrazen at (no spam) nejm.org, letters at (no spam) courant.com, Jgerberding at (no spam) cdc.gov,
michael.cole at (no spam) po.state.ct.us, conndcj at (no spam) po.state.ct.us, executive-
editor at (no spam) nytimes.com, managing-editor at (no spam) nytimes.com, news-
tips at (no spam) nytimes.com, bizday at (no spam) nytimes.com, foreign at (no spam) nytimes.com,
national at (no spam) nytimes.com, dvbid at (no spam) cdc.gov, brigidcallahan at (no spam) optonline.net,
trvl at (no spam) hotmail.com, illinoislyme at (no spam) aol.com, jlender at (no spam) courant.com,
tinajgarcia at (no spam) yahoo.com, jhornberger at (no spam) fff.org, thomas.carson at (no spam) usdoj.gov,
thomas.ryan at (no spam) po.state.ct.us, kurtzh at (no spam) washpost.com,
georgewill at (no spam) washpost.com, pj at (no spam) allegorypress.com,
commissioner.dcf at (no spam) po.state.ct.us, bransfield at (no spam) comcast.net,
vtsherr at (no spam) comcast.net, oca at (no spam) po.state.ct.us, freethinker at (no spam) charter.net,
scott.murphy at (no spam) po.state.ct.us, governor.rell at (no spam) po.state.ct.us,
attorney.general at (no spam) po.state.ct.us, randall.samborn at (no spam) usdoj.gov,
Robert.shiller at (no spam) yale.edu, editor at (no spam) greenwich-post.com,
harold.koh at (no spam) yale.edu, sedmonds at (no spam) nswbc.org, rrmcgovern at (no spam) aol.com,
frich at (no spam) nytimes.com, dprice at (no spam) stmartin.edu
Cc: francam at (no spam) ucia.gov, dr-ahmadinejad at (no spam) president.ir,
eugenerobinson at (no spam) washpost.com, afauci at (no spam) niaid.nih.gov,
bmiller at (no spam) newstimes.com, trvl at (no spam) hotmail.com, rastro18 at (no spam) aol.com,
billcurryct at (no spam) gmail.com, amcguigan at (no spam) rms-law.com, rjmurzyn at (no spam) aol.com,
paulcraigroberts at (no spam) yahoo.com, sidney_blumenthal at (no spam) yahoo.com,
criminal.division at (no spam) usdoj.gov, karla.dobinski at (no spam) usdoj.gov,
christopher.christie at (no spam) usdoj.gov, richard.Levin at (no spam) yale.edu,
harold.koh at (no spam) yale.edu, james.phillips at (no spam) yale.edu, inquire at (no spam) aldf.com,
lyme at (no spam) idsociety.org, meganmcardle at (no spam) theatlantic.com,
bob.drogin at (no spam) latimes.com
Subject: Tufts to try the Mouse Infectivity Test
Date: Oct 27, 2009 12:07 PM
ARTICLE BELOW
========================
Tufts to try the Mouse Infectivity Test:
http://www.actionlyme.org/IDSA_CYST_VIABLE.htm
HEEEYYY Good Idea!!
One tried 60 years ago with Syphilis!!
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC105309/?tool=pubmed
Referenced already by many of the Lyme
crooks, who simultaneously call the CT AG
a liar:
http://scholar.google.com/scholar?q=link:http://mic.sgmjournals.org/cgi/content/abstract/146/1/119
http://www.actionlyme.org/080430_RICO_CABAL_CAVES.htm
http://www.actionlyme.org/BRAIN_PERMANENT.htm
I guess the crooks decided they could no
longer uphold the charade.
And Klempner already knows Lyme is a permanent
intracellular brain infection, resistAnt to ceftriaxone:
http://www.actionlyme.org/MarkKlempner_Fibroblasts.htm
http://www.actionlyme.org/MKLEMPNER.htm
But that does not mean Lyme alone is causing
all of our illness signs. LYMErix and Lyme
victims carry a variety show:
http://www.actionlyme.org/Pam3Cys_Version15.htm
We ^^^ probably wouldn't even test positive
to a TB test.
Get the danger of that?
Duh.
I guess we will be "hearing it from
the horses mouth" again:
http://www.actionlyme.org/ALLFRYT.htm
Kathleen M. Dickson
http://www.actionlyme.org
=====================
http://www.eurekalert.org/pub_releases/2009-10/tuhs-tca102709.php
Public release date: 27-Oct-2009
[ Print | E-mail | Share Share ] [ Close Window ]
Contact: Randi Triant
617-636-9845
Tufts University, Health Sciences
Tufts CTSI and Tufts University receive 4 NIH supplemental grant
awards
The Tufts Clinical and Translational Science Institute (CTSI) and
Tufts University today announced they are the recipients of four
supplemental grant awards from the National Institutes of Health.
These new awards, totaling approximately $1.73 million, are
supplements to the original Clinical and Translational Science Award
(CTSA) grant, UL1 RR025752 that Tufts University received in 2008 from
the National Center for Research Resources.
"Community Engagement Research" is a two-year project that will expand
the scope of Tufts CTSI's current community engagement program by
enhancing the ability of community partners to participate more
effectively in the development of research plans and outcomes. Begun
in September 2009, the project has already established an alliance
between the Tufts CTSI, the Harvard Clinical and Translational Science
Center, and two pivotal community partners, the Center for Community
Health Education, Research, and Service (CCHERS) and the Immigrant
Service Providers Group/Health (ISG/H). This alliance is creating a
curriculum and evaluation for a self-study and face-to-face program
entitled "Fostering Community Partners in Translational Research
(FCPTR)" that will target community agencies and health centers. The
Program Director is Laurel Leslie, MD, MPH, Associate Professor of
Medicine at Tufts University School of Medicine.
"Improving BPD Predictors and Outcomes for Clinical Trials" builds on
prior landmark research that identified a constellation of signs and
symptoms in high risk newborns to accurately define bronchopulmonary
dysplasia (BPD) and predict the subsequent development of chronic
respiratory morbidity (CRM) later in childhood and adolescence. While
treatment with recombinant human superoxide dismutase to premature
newborns has been proven to have a 55% reduction in CRM compared to
placebo controls, current definitions of BPD may be unreliable
predictors of CRM and a more robust reduction in CRM is needed.
Superoxide dismutase is an enzyme that converts superoxide radicals
(highly reactive oxygen molecules produced during metabolism and
capable of damaging body tissues) into less toxic agents. This one-
year study is a prospective, longitudinal, observational study in 85
preterm infants 24-29 weeks gestation. The Program Director is
Jonathan Davis, MD, Chief of Newborn Medicine, The Floating Hospital
for Children at Tufts Medical Center, Program Director at the Clinical
and Translational Research Center, and Professor of Pediatrics, Tufts
University School of Medicine. Partners in this study include Brigham
and Women's Hospital (Harvard University), Beth Israel Hospital
(Harvard University), Nationwide Children's Hospital (Ohio State), and
King's College in London.
"Searching for Persistence of Infection in Lyme Disease" is a highly
innovative Bench-to- Bedside research project that could have an
extraordinarily significant impact on the field of Lyme disease.
Although antibiotic therapy is clinically effective in treating the
symptoms of Lyme disease for most patients early in the course of
disease, a significant number of patients who receive therapy report
persistent symptoms. A range of theories have been proposed for why
this occurs. Moreover, commonly available tests for human Lyme disease
are not able to determine persistent infection after antibiotic
therapy. Program Director, Linden Hu, MD (Associate Professor of
Medicine, Tufts University School of Medicine and Associate Professor
of Microbiology, Sackler School of Biomedical Graduate Sciences) has
begun an unconventional study examining whether xenodiagnosis (the
feeding of uninfected Ixodes ticks on infected animals) can be used to
determine when persistent infection occurs in humans. Xenodiagnosis
has been used for other difficult to diagnose diseases such as Chagas
disease and can sometimes definitively identify the presence of an
organism in animals where other techniques cannot. Whether
xenodiagnosis is effective in humans is unknown. This two-year project
seeks to test the utility of xenodiagnosis for identifying persistence
of B. burgdorferi, the spirochetal bacteria that cause Lyme disease,
after antibiotic treatment of the disease. Dr. Linden's team will test
subjects with elevated C6 antibody levels or persistent symptoms after
antibiotic therapy and patients with Lyme arthritis. Evidence that B.
burgdorferi can be identified by xenodiagnosis after antibiotic
therapy in subjects with continued symptoms would significantly change
the current paradigm for potential mechanisms of disease and provide
researchers and clinicians with a novel tool for identifying patients
with persistent infection.
Tufts CTSI currently has a Pilot Studies Program that funds new
interdisciplinary research teams, seeds novel ideas, and provides the
means to acquire necessary preliminary data for larger, multi-year
grant applications. A new supplemental project, The Pilot Project
Mechanism, is led by Susan K. Parsons, MD, MRP, Director, The Health
Institute, Institute for Clinical Research and Health Policy Studies
and Associate Professor of Medicine and Pediatrics, Tufts University
School of Medicine, and Amy Yee, PhD, Professor of Biochemistry,
Sackler School of Biomedical Graduate Sciences. This two-year project
expands the current program to influence research not just within the
Tufts enterprise, but also throughout the Commonwealth of
Massachusetts and into New England via Tufts CTSI's forty-three
collaborating partners by soliciting interinstitutional and
multidisciplinary applications. Many of the identified programs will
hire and support undergraduate and graduate students and postdoctoral
fellows, thereby creating jobs throughout New England and also
increasing the pipeline for translational researchers.
###
About Tufts Clinical and Translational Science Institute (CTSI)
Tufts CTSI was established in August 2008 with Grant Number UL1
RR025752 from the National Center for Research Resources (NCRR),
National Institutes of Health (NIH). A collaboration of organizations,
founded by Tufts Medical Center and Tufts University, Tufts CTSI
accelerates the translation of laboratory research into clinical use,
medical practice and health policy. It connects people to research
resources, consultation, and education, and fosters collaboration with
scholars of all disciplines and with community members, with the
ultimate goal of improving the health of the public. Website: www.tuftsctsi.org.
About NCRR and the CTSA Consortium
The National Center for Research Resources (NCRR), a part of the
National Institutes of Health (NIH), provides laboratory scientists
and clinical researchers with the tools and training they need to
understand, detect, treat, and prevent a wide range of diseases. NCRR
supports all aspects of clinical and translational research,
connecting researchers, patients, and communities across the nation.
Through programs such as the Clinical and Translational Science
Awards, NCRR brings together innovative research teams and equips them
with essential tools and critical resources needed to tackle the
nation's complex health problems.
About the NIH
The National Institutes of Health (NIH), a part of the U.S. Department
of Health and Human Services, is the primary Federal agency for
conducting and supporting medical research. Helping to lead the way
toward important medical discoveries that improve people's health and
save lives, NIH scientists investigate ways to prevent disease as well
as the causes, treatments, and even cures for common and rare
diseases. Composed of 27 Institutes and Centers, the NIH provides
leadership and financial support to researchers in every state and
throughout the world. For more information about NIH and its programs,
visit www.nih.gov.
"[Real] scientists are *fiercely* independent. That's the good
news."-- NIH's Top Fool, Anthony Fauci |
|
|
